CLOs on the Move

VentiRx Pharmaceuticals

www.ventirx.com

 
VentiRx Pharmaceuticals Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.ventirx.com
  • 12481 High Bluff Dr Ste 200
    San Diego, CA USA 92130
  • Phone: 858.436.1530

Executives

Name Title Contact Details

Similar Companies

Artemisia BioMedical

Artemisia BioMedical is a Renton, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bruker

Right from the beginning, which is now more than fifty years ago, Bruker has been driven by a single idea: to provide the best technological solution for each analytical task` Today, worldwide, more than 6,500 employees in over 90 locations on all continents are focusing their efforts on this permanent challenge` Bruker systems cover a broad spectrum of applications in all fields of research and development and are used in all industrial production processes for the purpose of ensuring quality and process reliability` Bruker continues to build upon its extensive range of products and solutions, expand its broad base of installed systems and maintain a strong reputation amongst its customers` As one of the world's leading analytical instrumentation companies, Bruker remains focused on developing state-of-the-art technologies and innovative solutions for today’s ever complex analytical questions` Bruker - Innovation with Integrity`

ALCON LABORATORIES INC

ALCON LABORATORIES INC is a Fort Worth, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zuni Technologies Inc

Zuni Technologies Inc is a Zuni, NM-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Cerulean

The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting Platform to create a portfolio of NDCs designed to selectively attack tumor cells, reduce toxicity by sparing the body’s normal cells, and enable therapeutic combinations. Our first platform-generated candidate, CRLX101, is in multiple clinical trials in combination with other cancer treatments, all of which aim to unlock the power of combination therapy. Our second platform-generated candidate, CRLX301, is in a Phase 1/2a clinical trial.